Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00732641 · OUTCOME

Number of Days of Overall Survival (OS)

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) · Source last updated 2017-04-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Days
Interval / dispersion
95% Confidence Interval
Time frame
Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)

What was measured

OS was calculated from the date of randomization to the date of death for any cause. Participants alive at the end of study were censored at the last date they were known to be alive. Participants who were still living at the end of the study were censored on the last date they were known to be alive.

Analysis population: Intent-to-treat population (those who received at least one dose of study drug)

Groups in this outcome

Peginterferon α-2b

Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.

No Treatment

Participants were observed and received no treatment

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Peginterferon α-2b122
No Treatment121

Reported measurements

Source class 1
Values in Days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Peginterferon α-2b2333Not reported2255NAnot available - some participants were still living at the end of the study
No Treatment2329Not reported1539NAnot available - some participants were still living at the end of the study
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        not available - some participants were still living at the end of the study
        group Id
        OG000
        lower Limit
        2255
        upper Limit
        NA
        value
        2333
      2. comment
        not available - some participants were still living at the end of the study
        group Id
        OG001
        lower Limit
        1539
        upper Limit
        NA
        value
        2329
denoms
  1. counts
    1. group Id
      OG000
      value
      122
    2. group Id
      OG001
      value
      121
    units
    Participants
description
OS was calculated from the date of randomization to the date of death for any cause. Participants alive at the end of study were censored at the last date they were known to be alive. Participants who were still living at the end of the study were censored on the last date they were known to be alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
    id
    OG000
    title
    Peginterferon α-2b
  2. description
    Participants were observed and received no treatment
    id
    OG001
    title
    No Treatment
param Type
MEDIAN
population Description
Intent-to-treat population (those who received at least one dose of study drug)
reporting Status
POSTED
time Frame
Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)
title
Number of Days of Overall Survival (OS)
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice